FY 2016 BsUFA Financial Report
Required by the
Biosimilar User Fee Act
Food and Drug Administration
Department of Health and Human Services
April 2017
Printable Version of FY 2016 BsUFA Financial Report
Table of Contents
- Executive Summary-FY 2016 BsUFA Financial Report
- Background-FY 2016 BsUFA Financial Report
- Legal Conditions-FY2016 BsUFA Financial Report
- User Fee Collections-FY2016 BsUFA Financial Report
- User Fee Obligations-FY2016 BsUFA Financial Report
- Carryover Balances-FY2016 BsUFA Financial Report
- Reserves and Balances Available for Allocation-FY2016 BsUFA Financial Report
- Total BsUFA Program Costs-FY2016 BsUFBA Financial Report
- Full-Time Equivalent-FY2016 BsUFA Financial Report
Appendices
- Appendix A-Conditions for Assessment and Use of Fees
- Appendix B-Fees and Waivers
- Appendix C-Allowable and Excluded Costs
- Appendix D-Development of Costs for the BsUFA Program